Drexel, H; Coats, AJS; Spoletini, I; Bilato, C; Mollace, V; Perrone Filardi, P; Rosano, GMC
(2020)
An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.
Eur Heart J Cardiovasc Pharmacother, 6 (2).
pp. 115-121.
ISSN 2055-6845
https://doi.org/10.1093/ehjcvp/pvz079
SGUL Authors: Rosano, Giuseppe Massimo Claudio
|
PDF
Accepted Version
Available under License ["licenses_description_publisher" not defined]. Download (975kB) | Preview |
Abstract
Benefits and safety on statins have been well-established over 20 years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the ESC Working Group on Cardiovascular Pharmacotherapy in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe.
| Item Type: | Article |
|---|---|
| Additional Information: | This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal: Cardiovascular Pharmacotherapy following peer review. The version of record Heinz Drexel, Andrew J S Coats, Ilaria Spoletini, Claudio Bilato, Vincenzo Mollace, Pasquale Perrone Filardi, Giuseppe M C Rosano, An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 2, March 2020, Pages 115–121 is available online at: https://doi.org/10.1093/ehjcvp/pvz079 Corrigendum available at https://doi.org/10.1093/ehjcvp/pvaa069 |
| Keywords: | Ezetimibe, Low-density lipoprotein cholesterol, PCSK9 inhibitors, Position paper, Statin intolerance, Statins adherence, Anticholesteremic Agents, Biomarkers, Cardiovascular Diseases, Cholesterol, LDL, Down-Regulation, Drug Therapy, Combination, Dyslipidemias, Ezetimibe, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Medication Adherence, Proprotein Convertase 9, Risk Assessment, Risk Factors, Serine Proteinase Inhibitors, Treatment Outcome, Humans, Cardiovascular Diseases, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Serine Proteinase Inhibitors, Treatment Outcome, Drug Therapy, Combination, Risk Assessment, Risk Factors, Down-Regulation, Dyslipidemias, Cholesterol, LDL, Medication Adherence, Biomarkers, Ezetimibe, Proprotein Convertase 9, PCSK9 inhibitors, Statins adherence, ezetimibe, low-density lipoprotein cholesterol, position paper, statin intolerance |
| SGUL Research Institute / Research Centre: | Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) |
| Journal or Publication Title: | Eur Heart J Cardiovasc Pharmacother |
| ISSN: | 2055-6845 |
| Language: | eng |
| Publisher License: | Publisher's own licence |
| PubMed ID: | 31873726 |
 |
Go to PubMed abstract |
| URI: | https://openaccess.sgul.ac.uk/id/eprint/111911 |
| Publisher's version: | https://doi.org/10.1093/ehjcvp/pvz079 |
Statistics
Actions (login required)
 |
Edit Item |